Polygenic contribution for familial hypercholesterolemia (FH)

التفاصيل البيبلوغرافية
العنوان: Polygenic contribution for familial hypercholesterolemia (FH)
المؤلفون: Mafalda Bourbon, Ana Margarida Medeiros
المصدر: Current opinion in lipidology. 32(6)
سنة النشر: 2021
مصطلحات موضوعية: Multifactorial Inheritance, Apolipoprotein B, Endocrinology, Diabetes and Metabolism, Population, Hypercholesterolemia, Familial hypercholesterolemia, medicine.disease_cause, Hyperlipoproteinemia Type II, Genetic variation, Genetics, medicine, Humans, LPA variants, education, Molecular Biology, Mutation, education.field_of_study, Nutrition and Dietetics, Polygenic hypercholesterolaemia, biology, business.industry, PCSK9, Cell Biology, Genetic Status, medicine.disease, Genetic risk score, Receptors, LDL, LDL receptor, biology.protein, lipids (amino acids, peptides, and proteins), Familial Hypercholesterolaemia, Proprotein Convertase 9, Cardiology and Cardiovascular Medicine, business
الوصف: Purpose of review: The present review summarizes different polygenic risk scores associated with hypercholesterolemia applied to cohorts with a genetic diagnosis of familial hypercholesterolemia (FH). Recent findings: Several single-nucleotide polymorphisms associated with increased levels of LDL-C or Lp(a) have been genotyped in population cohorts with FH phenotype, to identify the cause of hypercholesterolemia in mutation negative individuals. In different studies, a large proportion of individuals without a monogenic causative variant (in low density lipoprotein receptor gene (LDLR), apolipoprotein B gene (APOB) or proprotein convertase subtilisin/kexin type 9 gene (PCSK9 genes) was considered to have a hypercholesterolemia with a polygenic basis. The heterogeneity in the phenotype of monogenic FH may also be explained by polygenic contributions to LDL-C. The elevated LDL-C genetic risk score (GRS) has been associated with increased risk of atherosclerotic cardiovascular disease in individuals with monogenic FH. Moreover, a poorer response to lipid lowering therapy has been associated with monogenic FH when compared to a polygenic basis. The reason why Lp(a) concentrations are raised in individuals with clinical FH is unclear, but it could be caused by a genetic variation in Lipoprotein(A) gene as a polygenic contribution. Summary: Polygenic risk scores have revealed to be important tools to define the cause of hypercholesterolemia in FH mutation-negative individuals and should be included in FH diagnosis strategies, although there is still space for more specific LDL-C GRS to be developed. The use of GRS may be used to refine cardiovascular risk prediction in FH patients and could lead to a personalized approach to therapy. The identification of the genetic status of an individual with FH phenotype (monogenic or polygenic) may have implications on their risk stratification, cascade screening of relatives, disease management and therapeutic measures. A.M.M. was supported by a PhD fellowship (2016-2019) from Science and Technology Foundation (Ref. SFRH/BD/113017/2015). info:eu-repo/semantics/publishedVersion
تدمد: 1473-6535
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd3e17b99221a64354730242bbfdc5aaTest
https://pubmed.ncbi.nlm.nih.gov/34751168Test
حقوق: OPEN
رقم الانضمام: edsair.doi.dedup.....dd3e17b99221a64354730242bbfdc5aa
قاعدة البيانات: OpenAIRE